Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Drug Class Type Segment
1.1.1.2. Age Group Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Primary Sources
1.11. List of Abbreviations
Chapter 2. Prediabetes Market: Executive Summary
2.1. Market Snapshot
2.2. Drug Class Snapshot
2.3. Age group Type Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Prediabetes Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Increasing global prevalence of prediabetes
3.4.2. Growing awareness and early disease diagnosis due to advanced diagnostic technologies
3.4.3. Favorable government initiatives
3.5. Market Restraint Analysis
3.5.1. Limited FDA-approved treatment options
3.5.2. Regulatory and reimbursement challenges
3.6. Prediabetes Market Analysis Tools
3.6.1. Industry Analysis - Porter’s
3.6.1.1. Supplier Power
3.6.1.2. Buyer Power
3.6.1.3. Substitution Threat
3.6.1.4. Threat of New Entrant
3.6.1.5. Competitive Rivalry
3.6.2. PESTLE Analysis
3.6.2.1. Political Landscape
3.6.2.2. Technological Landscape
3.6.2.3. Economic Landscape
3.6.3. Pricing Analysis
3.6.4. Target Population Analysis
3.6.5. Alternative Medicine Analysis (Qualitative)
3.6.6. Total Addressable Market Analysis
Chapter 4. Prediabetes: Drug Class Estimates & Trend Analysis
4.1. Global Prediabetes Market: Drug Class Segment Dashboard
4.2. Global Prediabetes Market: Drug Class Movement Analysis
4.3. Global Prediabetes Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. Diguanide
4.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.5. Thiazolidinediones
4.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.6. Glucagon-like peptide-1 agonists (GLP-1)
4.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.7. SGLT2 inhibitors
4.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.8. DPP-4 inhibitors
4.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.9. Others
4.9.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
Chapter 5. Prediabetes: Age Group Estimates & Trend Analysis
5.1. Global Prediabetes Market: Age Group Segment Dashboard
5.2. Global Prediabetes Market: Age Group Movement Analysis
5.3. Global Prediabetes Market Size & Trend Analysis, by Age Group, 2018 to 2030 (USD Million)
5.4. Children (12-18 years)
5.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.5. Adults (18-49)
5.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.6. Elderly (50+)
5.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
Chapter 6. Regional Business Analysis
6.1. Regional Market Dashboard
6.2. Global Regional Market Snapshot
6.3. Marker Size, & Forecasts Trend Analysis, 2018 to 2030:
6.4. North America
6.4.1. U.S.
6.4.1.1. Key Country Dynamics
6.4.1.2. Competitive Scenario
6.4.1.3. Regulatory Framework/Reimbursement Framework
6.4.1.4. U.S. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.4.2. Canada
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework/Reimbursement Framework
6.4.2.4. Canada Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5. Europe
6.5.1. UK
6.5.1.1. Key Country Dynamics
6.5.1.2. Competitive Scenario
6.5.1.3. Regulatory Framework/Reimbursement Framework
6.5.1.4. UK Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.2. Germany
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework/Reimbursement Framework
6.5.2.4. Germany Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.3. Spain
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework/Reimbursement Framework
6.5.3.4. Spain Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework/Reimbursement Framework
6.5.4.4. France Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Competitive Scenario
6.5.5.3. Regulatory Framework/Reimbursement Framework
6.5.5.4. Italy Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.6. Denmark
6.5.6.1. Key Country Dynamics
6.5.6.2. Competitive Scenario
6.5.6.3. Regulatory Framework/Reimbursement Framework
6.5.6.4. Denmark Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.7. Sweden
6.5.7.1. Key Country Dynamics
6.5.7.2. Competitive Scenario
6.5.7.3. Regulatory Framework/Reimbursement Framework
6.5.7.4. Sweden Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5.8. Norway
6.5.8.1. Key Country Dynamics
6.5.8.2. Competitive Scenario
6.5.8.3. Regulatory Framework/Reimbursement Framework
6.5.8.4. Norway Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Japan
6.6.1.1. Key Country Dynamics
6.6.1.2. Competitive Scenario
6.6.1.3. Regulatory Framework/Reimbursement Framework
6.6.1.4. Japan Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.6.2. China
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework/Reimbursement Framework
6.6.2.4. China Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.6.3. India
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework/Reimbursement Framework
6.6.3.4. India Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.6.4. South Korea
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework/Reimbursement Framework
6.6.4.4. South Korea Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.6.5. Thailand
6.6.5.1. Key Country Dynamics
6.6.5.2. Competitive Scenario
6.6.5.3. Regulatory Framework/Reimbursement Framework
6.6.5.4. Thailand Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.6.6. Australia
6.6.6.1. Key Country Dynamics
6.6.6.2. Competitive Scenario
6.6.6.3. Regulatory Framework/Reimbursement Framework
6.6.6.4. Australia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.7. Latin America
6.7.1. Brazil
6.7.1.1. Key Country Dynamics
6.7.1.2. Competitive Scenario
6.7.1.3. Regulatory Framework/Reimbursement Framework
6.7.1.4. Brazil Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.7.2. Mexico
6.7.2.1. Key Country Dynamics
6.7.2.2. Competitive Scenario
6.7.2.3. Regulatory Framework/Reimbursement Framework
6.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Competitive Scenario
6.7.3.3. Regulatory Framework/Reimbursement Framework
6.7.3.4. Argentina Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.8. MEA
6.8.1. South Africa
6.8.1.1. Key Country Dynamics
6.8.1.2. Competitive Scenario
6.8.1.3. Regulatory Framework/Reimbursement Framework
6.8.1.4. South Africa Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.8.2. Saudi Arabia
6.8.2.1. Key Country Dynamics
6.8.2.2. Competitive Scenario
6.8.2.3. Regulatory Framework/Reimbursement Framework
6.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.8.3. UAE
6.8.3.1. Key Country Dynamics
6.8.3.2. Competitive Scenario
6.8.3.3. Regulatory Framework/Reimbursement Framework
6.8.3.4. UAE Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.8.4. Kuwait
6.8.4.1. Key Country Dynamics
6.8.4.2. Competitive Scenario
6.8.4.3. Regulatory Framework/Reimbursement Framework
6.8.4.4. Kuwait Market Estimates and Forecasts, 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company /Competition Categorization
7.2. Participant Overview
7.3. Financial Performance
7.4. Product Overview
7.5. Company Market Share Analysis
7.6. Strategy Mapping, 2023
7.6.1. SciMar
7.6.1.1. Overview
7.6.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.1.3. Product Benchmarking
7.6.1.4. Strategic Initiatives
7.6.2. Boston Therapeutics
7.6.2.1. Overview
7.6.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.2.3. Product Benchmarking
7.6.2.4. Strategic Initiatives
7.6.3. Valbiotis
7.6.3.1. Overview
7.6.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.3.3. Product Benchmarking
7.6.3.4. Strategic Initiatives
7.6.4. RESVERLOGIX
7.6.4.1. Overview
7.6.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.4.3. Product Benchmarking
7.6.4.4. Strategic Initiatives
7.6.5. Caelus Health
7.6.5.1. Overview
7.6.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.5.3. Product Benchmarking
7.6.5.4. Strategic Initiatives
7.6.6. Aphaia Pharma
7.6.6.1. Overview
7.6.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.6.3. Product Benchmarking
7.6.6.4. Strategic Initiatives
7.6.7. AstraZeneca
7.6.7.1. Overview
7.6.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.7.3. Product Benchmarking
7.6.7.4. Strategic Initiatives
7.6.8. Bristol-Myers Squibb
7.6.8.1. Overview
7.6.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.8.3. Product Benchmarking
7.6.8.4. Strategic Initiatives